Age (years)
|
66
|
60
|
31
|
63
|
63
|
Sex
|
Female
|
Male
|
Female
|
Male
|
Male
|
BMI (kg/m2)
|
20.9
|
24.2
|
29.3
|
19.4
|
25.4
|
History of oncologic treatment of the liver
|
Hemihepatectomy
|
Radio-embolisation
|
Partial hepatectomy
|
None
|
None
|
TAS-102 dosage
|
50 mg b.i.d.
|
65 mg b.i.d.
|
55 mg b.i.d.
|
60 mg b.i.d.
|
70 mg b.i.d.
|
Cycle number
|
Cycle 2 day 8
|
Cycle 1 day 9
|
Cycle 1 day 9
|
Cycle 1 day 9
|
Cycle 1 day 9
|
Time of response evaluation according to RECIST
|
After 4 cycles TAS-102
|
After 3 cycles TAS-102
|
After 3 cycles TAS-102
|
After 3 cycles TAS-102
|
After 3 cycles TAS-102
|
Time to first disease progression (progression-free survival)
|
3.7 months
|
2.8 months
|
2.8 months
|
2.8 months
|
2.8 months
|
Time between oral intake of TAS-102 and first MRS examination
|
30 min
|
90 min
|
105 min
|
150 min
|
60 min
|
Timing of both localised CSI scans
|
14.24 min
|
14.24 min
|
14.24 min
|
14.24 min
|
14.24 min
|